Texas Permanent School Fund Corp Grows Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Texas Permanent School Fund Corp grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 9.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,282 shares of the biotechnology company’s stock after acquiring an additional 2,887 shares during the quarter. Texas Permanent School Fund Corp owned about 0.08% of REGENXBIO worth $665,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of RGNX. Captrust Financial Advisors grew its holdings in shares of REGENXBIO by 742.1% during the first quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 846 shares during the last quarter. Royal Bank of Canada increased its position in REGENXBIO by 189.8% during the third quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 915 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in REGENXBIO in the fourth quarter valued at about $38,000. Headlands Technologies LLC bought a new stake in shares of REGENXBIO during the 2nd quarter valued at about $44,000. Finally, Robeco Institutional Asset Management B.V. purchased a new position in shares of REGENXBIO in the first quarter worth approximately $48,000. 88.80% of the stock is currently owned by institutional investors.

REGENXBIO Price Performance

REGENXBIO stock opened at $20.03 on Tuesday. The stock has a market cap of $881.12 million, a P/E ratio of -3.35 and a beta of 1.12. REGENXBIO Inc. has a 1 year low of $12.82 and a 1 year high of $25.54. The firm’s 50 day moving average price is $16.65 and its 200-day moving average price is $18.06.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.44) by $0.03. The firm had revenue of $28.90 million during the quarter, compared to analyst estimates of $26.14 million. REGENXBIO had a negative return on equity of 59.54% and a negative net margin of 262.18%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted ($1.75) earnings per share. As a group, equities analysts expect that REGENXBIO Inc. will post -4.98 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on RGNX. Royal Bank of Canada reiterated a “sector perform” rating and issued a $20.00 price target on shares of REGENXBIO in a research report on Wednesday, October 4th. StockNews.com began coverage on REGENXBIO in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Wedbush restated a “neutral” rating and issued a $20.00 price target on shares of REGENXBIO in a research report on Thursday, October 5th. William Blair reiterated a “neutral” rating and issued a $21.00 price target (up from $20.00) on shares of REGENXBIO in a research report on Tuesday, November 14th. Finally, Stifel Nicolaus initiated coverage on shares of REGENXBIO in a research report on Wednesday, November 1st. They issued a “buy” rating and a $35.00 price target for the company. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $31.13.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.